Preservative Composition
Levulinic acid derivatives enhance preservative efficacy in personal care and cosmetic products by providing synergistic antimicrobial protection across a wide pH range, reducing the need for higher preservative concentrations and addressing regulatory challenges.
Patent Information
- Application Number
- JP2024525335
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-19
- Filing Date
- 2022-11-15
- Publication Date
- 2024-12-05
AI Technical Summary
Existing preservatives in personal care and cosmetic products lose effectiveness at neutral or higher pH levels, necessitating higher concentrations to compensate, which is economically undesirable and faces regulatory pressure, while maintaining broad-spectrum antimicrobial efficacy across varying pH ranges is challenging.
Incorporating levulinic acid derivatives, such as levulinic acid esters or ketals, into preservative compositions to enhance antimicrobial effectiveness synergistically, allowing for reduced preservative amounts while maintaining efficacy across a wide pH range.
The synergistic interaction between preservatives and levulinic acid derivatives provides enhanced antimicrobial activity, enabling lower preservative concentrations to maintain effectiveness from pH 4 to 9, ensuring broad-spectrum protection and stability during formulation processes.
Smart Images

Figure 2024544850000001 
Figure 2024544850000002 
Figure 2024544850000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a preservative composition containing a preservative and a potentiator component, and to end-use formulations comprising said preservative composition. [Background technology]
[0002] Microbial contamination of personal care products, cosmetics, home care products and other similar products is a very important problem for the personal care industry. Microbial contamination can be a major cause of product loss of end-use formulations and can cause significant economic losses. Furthermore, contamination of cosmetics and home care products can result in the conversion of products that are harmful to consumers. Certain preservatives and preservative compositions are known in the art to protect against microbial attack from either bacterial or fungal sources. These preservatives have a wide variety of applications in areas such as personal care products, cosmetics, home care products, and health and hygiene products.
[0003] Personal care products span a wider range of pH and therefore require preservative systems to maintain their shelf life. However, many of the preservatives are organic acids or salts of organic acids, which cannot ensure preservation above their pKa points, especially at pHs approaching neutral pH or above. This is why short organic acids (and their salts) dissociate above their pKa and they can no longer provide antimicrobial effects.
[0004] Although higher concentrations of preservatives in personal care products can at least partially compensate for this loss of preservative effectiveness at or near neutral pH, there is ongoing regulatory pressure to reduce the amount of preservatives in end-use formulations.Similarly, in the field of personal care products, there is ongoing regulatory pressure to reduce the amount of active ingredients in personal care products.Furthermore, there is ongoing regulatory pressure to stop using certain traditional preservatives or to reduce the amount of certain traditional preservatives in end-use formulations.From an economic perspective, it is also desirable to reduce the amount of preservatives to a minimum.
[0005] Thus, a need exists for preservative compositions that contain fewer active ingredients or preservatives while maintaining an acceptable level of overall antimicrobial effectiveness. Summary of the Invention [Problem to be solved by the invention]
[0006] The object of the present invention is to provide a preservative composition that can be used in a variety of compositions, such as home and personal care formulations, that requires a small amount of preservative while ensuring good preservative effect. Furthermore, the preservative composition of the present invention can provide a broad spectrum preservative activity that is effective over a wide pH range. [Means for solving the problem]
[0007] This object is solved by the preservative composition of the present invention.
[0008] In one aspect of the invention, there is provided a preservative composition comprising: (i) at least one preservative; and (ii) at least one levulinic acid derivative selected from (a) a levulinic acid ester, or (b) a levulinic acid ketal, and combinations thereof, wherein the at least one levulinic acid derivative is present in an amount sufficient to enhance the effectiveness of the preservative compared to the preservative alone.
[0009] In another aspect of the present invention, there is provided an end-use formulation comprising the preservative composition of the present invention.
[0010] A further aspect of the present invention provides the use of a preservative composition according to the present invention for increasing effectiveness against microorganisms compared to an equivalent amount of a preservative not comprising the at least one levulinic acid derivative.
[0011] A further aspect of the present invention provides the use of at least one levulinic acid derivative selected from (a) a levulinic acid ester or (b) a levulinic acid ketal, and combinations thereof, to increase the effectiveness of at least one preservative against microorganisms compared to an equivalent amount of the preservative without the at least one levulinic acid derivative.
[0012] A further aspect of the present invention provides a method for preventing microbial spoilage of an end-use formulation, the method comprising adding to the end-use formulation a preservative composition according to the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] As already outlined above, the present invention relates to a preservative composition comprising (i) at least one preservative and (ii) at least one levulinic acid derivative selected from (a) levulinic acid esters or (b) levulinic acid ketals and combinations thereof. In one embodiment, the at least one levulinic acid derivative is present in an amount sufficient to enhance the effectiveness of the preservative compared to the preservative alone.
[0014] As used herein, the term "preservative" means a biocide or biocidal composition that is intended to be blended into end-use formulations, such as personal care products, cosmetics, home care products, and health and hygiene products, to prevent microorganisms from spoiling the end-use formulation or rendering the end-use formulation unusable for the particular purpose for which it was developed.
[0015] Surprisingly, it has been found that adding an amount of a levulinic acid derivative to a preservative composition containing a preservative intended for the end-use formulation can provide an effectively preserved end-use formulation having a synergistic interaction between the preservative and the levulinic acid derivative. Thus, the inventors have surprisingly found that the levulinic acid derivative acts as an enhancer of the preservative. Typically, the end-use formulation has a pH of 4 or greater. The end-use formulation can also have a pH of about neutral or greater, such as a pH of about 6 or greater. A pH of about 4 or greater includes a pH of 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, about 10 or greater. In one embodiment, at least one levulinic acid derivative is present in an amount sufficient to enhance the effectiveness of the preservative at a pH of 4 to 9, preferably 6 to 8, compared to the preservative alone.
[0016] As used herein, "synergistic interaction" refers to the fact that the preservative, when combined with the levulinic acid derivative, has a higher total antibacterial / antifungal effect than the antibacterial / antifungal properties of the preservative alone or the levulinic acid derivative alone. In other words, the preservative of the present invention acts synergistically with the levulinic acid derivative and has a greater antibacterial / antifungal activity in the presence of each against a certain microorganism compared to the antibacterial activity of the preservative alone or the levulinic acid derivative alone at the same concentration. Due to this synergistic effect, the amount of preservative present in the preservative composition can be reduced while still providing the desired effect. This effectiveness is also known as "enhancement" of the preservative in the preservative composition. This enhancement of the preservative is also referred to herein as "synergy" between the preservative and the levulinic acid derivative to enhance the effectiveness of the preservative.
[0017] Furthermore, the use of the preservative composition according to the present invention and the use of at least one levulinic acid derivative according to the present invention provide numerous technical advantages and benefits. For example, the preservative composition according to the present invention maintains broad-spectrum activity against all types of microorganisms at various pH levels. Also, the preservative composition according to the present invention generally remains stable during changes in temperature and changes encountered during the manufacture, packaging, shipping, and storage of the final formulation in which the preservative composition may be included. Furthermore, the preservative composition according to the present invention is physically and chemically compatible with the ingredients present in various end-use formulations. Finally, the preservative composition according to the present invention may contain a lower amount of preservative and still provide antimicrobial efficacy that meets industry standards.
[0018] The compositions of the invention can comprise, consist essentially of, or consist of the components of the invention as well as other components described herein. As used herein, "consisting essentially of" means that the composition or component may include additional components, but only if the additional components do not materially alter the basic and novel characteristics of the claimed composition or method.
[0019] As used herein, the term "about" modifying the amount of a substance, component, ingredient, or parameter used refers to variations in the numerical amount that may occur, for example, through typical measuring and handling procedures, such as liquid handling procedures used to make concentrates or solutions. Additionally, variations may result from inadvertent errors in measuring procedures, differences in manufacture, source, or purity of ingredients used to practice the invention. In one embodiment, the term "about" means within 10% of the reported numerical value. In a more specific embodiment, the term "about" means within 5% of the reported numerical value.
[0020] Suitable preservatives that can be used in the present invention include acid compounds and their salts, aldehydes, phenolic compounds, sulfites, iron chelating agents, aromatic alcohols, quaternary ammonium compounds, pyrone compounds, urea compounds, guanidine compounds, pyridine compounds, imidazole compounds, isothiazolinone compounds, amine compounds, or any combination thereof.
[0021] In one embodiment, the preservative may be an acid compound and its salts, including both aromatic and non-aromatic acids. Exemplary acids include, for example, benzoic acid, propionic acid, salicylic acid, sorbic acid, formic acid, undec-10-enoic acid, lactic acid, glycolic acid, levulinic acid, and citric acid. As used herein, the term "acid compound" is meant to include the respective salts of this acid. Examples of salts include lithium, sodium, potassium, magnesium, and calcium salts, such as sodium benzoate, sodium lactate, sodium levulinate, and potassium sorbate. In other words, all references to acids as preservatives include salts of such acids as well. Other salts may be used. Acid compounds are typically used as preservatives in end-use formulations in amounts up to about 3% by weight based on the weight of the end-use formulation, depending on the particular acid compound. Similar amounts may be used for salts. Typically, the acid or its salt is used in an amount of 1% by weight or less, for example 0.5% by weight or less, based on the weight of the end-use formulation. Mixtures of acids may also be used as preservatives.
[0022] Preferably, the acid compound and its salt are selected from the group consisting of benzoic acid or its salt, lactic acid or its salt, sorbic acid or its salt, levulinic acid or its salt, and combinations thereof. More preferably, the acid compound and its salt are selected from the group consisting of benzoic acid, sodium benzoate, lactic acid, sodium lactate, sorbic acid, potassium sorbate, levulinic acid, sodium levulinate, and combinations thereof. Even more preferably, the acid compound and its salt are selected from the group consisting of benzoic acid, sodium benzoate, lactic acid, sodium lactate, sorbic acid, potassium sorbate, and combinations thereof.
[0023] In another embodiment, the preservative may be an aldehyde. Exemplary aldehydes include, for example, formaldehyde and paraformaldehyde. Exemplary aldehyde-forming agents include imidazolidine compounds such as hydantoins, such as dimethylol dimethylhydantoin, (DMDMH) and other similar aldehyde-forming hydantoins. Depending on the use, the aldehyde may be present in the preserved composition in an amount of up to 0.3% by weight. Typically, the amount of aldehyde is up to 0.2% based on the weight of the preserved composition. A mixture of aldehydes can also be used as a preservative.
[0024] In further embodiments, the preservative may be a phenolic compound. Exemplary phenolic compounds include, for example, paraben compounds, biphenyl-2-ol (o-phenylphenol) or its salts, 4-chloro-m-cresol, 5-chloro-2-(2,4-dichlorophenoxy)phenol (triclosan), 4-chloro-3,5-dimethylphenol, 4-isopropyl-m-cresol, 2-benzyl-4-chlorophenol, and bromochlorophene. Exemplary paraben compounds include, for example, butylparaben, propylparaben, ethylparaben, methylparaben, and their salts (including, for example, potassium, sodium, and / or calcium salts). Phenolic compounds are typically used as preservatives in end-use formulations in amounts up to about 1% by weight based on the weight of the total end-use formulation. This upper limit depends on the particular phenolic compound. More typically, up to about 0.5% by weight of phenolic compounds are used in cosmetic formulations.
[0025] In yet another embodiment, the preservative may be a compound known as an iron chelator, the iron chelator being selected from pyrithione compounds, hydroxylpyridine compounds, and their salts. Pyrithione is known by several names, including 2-mercaptopyridine-N-oxide, 2-pyridinethiol-1-oxide (CAS Registry Number 1121-31-9), 1-hydroxypyridine-2-thione, and 1-hydroxy-2(1H)-pyridinethione (CAS Registry Number 1121-30-8). Pyrithione salts are commercially available from Arxada AG, such as sodium OMADINE® or zinc OMADINE®. Preferably, the hydroxylpyridine compound is 2-pyridinol-1-oxide (HPNO, also called 2-hydroxypyridine-N-oxide).
[0026] The pyrithione present as a preservative can be in water-insoluble or water-soluble form.The pyrithione can include sodium pyrithione, zinc pyrithione, barium pyrithione, strontium pyrithione, copper pyrithione, cadmium pyrithione, and / or zirconium pyrithione.Other pyrithiones that can be present in the composition include sodium pyrithione, bismuth pyrithione, potassium pyrithione, lithium pyrithione, ammonium pyrithione, calcium pyrithione, magnesium pyrithione, silver pyrithione, gold pyrithione, manganese pyrithione, and / or organic amine pyrithione.A single pyrithione can be present as a preservative, or any combination of the above can be included as a preservative.Preferably, the pyrithione is sodium pyrithione.
[0027] The pyrithione particles can have a particle size such that 100% of the particles have a particle size of less than about 10 microns, and at least 70% of the particles have a particle size of less than 5 microns, for example, at least about 50% of the particles can have a particle size of 1 micron or less. Particle size can be measured using a laser scattering particle size analyzer, such as a HORIBA LA 910 particle size analyzer.
[0028] Pyrithione particles can be produced by reacting pyrithione or a water-soluble salt of pyrithione with a water-soluble polyvalent metal salt in a pressurized turbulent flow reactor that generates a grinding force. The grinding force generated by the pressurized turbulent flow reactor effectively produces micron-sized pyrithione salt particles. The micron-sized pyrithione salt particles produced by this method have a narrow uniform size distribution and have excellent surface deposition properties due to the large surface area provided by the population of micron particles.
[0029] Iron chelating compounds are typically used as preservatives in end-use formulations in amounts up to about 1% by weight depending on the particular compound. Of particular interest are zinc pyrithione and piroctone olamine. These iron chelating agents may also have other advantages, such as providing other benefits including anti-dandruff properties.
[0030] In another embodiment, the preservatives may include inorganic sulfite and bisulfite compounds. The sulfite compounds are typically present in an amount up to about 0.5% by weight based on the total weight of the end use formulation.
[0031] In some embodiments, the preservative comprises an alcohol compound. The alcohol may be a lower alcohol or an aromatic alcohol. The lower alcohol is typically selected from among monofunctional low molecular weight alcohols, preferably alkanols having 1-4 carbon atoms, such as methanol, ethanol, isopropanol or butanol, or combinations thereof. Substituted alcohols such as chlorobutanol may also be used. Particularly suitable lower alcohols include ethanol and isopropyl alcohol. Aromatic alcohols may also be used. Suitable aromatic alcohols include phenoxyethanol, 2,4-dichlorophenyl)methanol, benzyl alcohol, 1-phenoxypropanol, chlorphenesin, and benzyl hemiformal. One particularly preferred alcohol is phenoxyethanol. Another particularly preferred alcohol is benzyl alcohol. The alcohol compound may be used as a preservative in the end-use formulation in an amount up to about 1.5% by weight based on the total weight of the end-use formulation, depending on the particular alcohol compound. In most cases, the amount of the alcohol compound is typically used in an amount up to about 1% by weight based on the weight of the end-use formulation, more typically up to about 0.5% by weight.
[0032] In another embodiment, one or more quaternary ammonium compounds can be used as preservatives. Quaternary ammonium compounds, also known as "quats," typically contain at least one quaternary ammonium cation with a suitable anion. Quats generally have the general formula (1): [ka]
[0033] The groups R1, R2, R3 and R4 may vary within a wide range and may have antibacterial properties. Typically, at least one, for example at least two, of R1, R2, R3 and R4 is a lower alkyl, meaning having 1 to 4 carbon atoms, such as a methyl, ethyl, propyl or butyl group. In one embodiment, at least one, for example at least two, of R1, R2, R3 and R4 is a longer chain alkyl group of 6 to 24 carbon atoms. R4 may also be a substituted or unsubstituted benzyl group, for example an ethylbenzyl group, or an alkoxy group. A- is a monovalent anion or an equivalent polyvalent anion of an inorganic or organic acid. Suitable anions for A- are in principle all inorganic or organic anions, in particular halides, for example chlorides or bromides, carbonates, bicarbonates, carboxylates, sulfonates, phosphates, propionates, saccharates or mixtures thereof. The carboxylates may be derived from lower carboxylic acids or fatty acids.
[0034] Alkyl is in the following taken to mean in each case unbranched or branched alkyl radicals of a certain number of carbons, but preferably unbranched alkyl radicals and particularly preferably alkyl radicals having an even number of carbon atoms. In particular, it is also taken to mean homolog mixtures derived from natural sources, such as "cocoalkyl".
[0035] In one embodiment, the quaternary ammonium compound may have the following R groups, where R, R, and R are alkyl groups; R is a benzyl group; 6~18 C such as alkyl group 1~18 Alkyl group, or the structure -[(CH2)2-O] nR1 is an alkoxy group such as a group having R5 (wherein n=1-20 and R5 is hydrogen or unsubstituted or substituted phenyl), and A- is, as described above, for example, a monovalent anion of an inorganic or organic acid or an equivalent polyvalent anion. For example, R1 is an alkyl group having 1-4 carbon atoms, and R2 and R3 are independently alkyl groups having 6-24 carbon atoms, or R1 and R2 are independently alkyl groups having 1-4 carbon atoms, and R3 is an alkyl group having 6-24 carbon atoms.
[0036] Suitable quaternary ammonium compounds include, for example, alkyl (C 12~22 ) Trimethylammonium bromide, alkyl(C 12~22 ) trimethylammonium chloride compounds (including, for example, cetrimonium bromide, cetrimonium chloride, laurtrimonium bromide, laurtrimonium chloride, steartrimonium bromide, and steartrimonium chloride or mixtures thereof), benzethonium compounds (including, for example, benzalkonium chloride, benzalkonium bromide, and benzalkonium saccharinate).
[0037] Suitable quaternary ammonium compounds include alkyldimethylbenzylammonium chlorides (ADBAC), preferably C 12 ~C 16 Alkyldimethylbenzylammonium chlorides include alkyldimethylbenzylammonium chlorides (ADBAC) are commercially available as Barquat® BAC-50 from Arxada AG.
[0038] In one embodiment, the quaternary ammonium compound may include a dialkylammonium compound, such as a dimethyldialkylammonium compound, which in one embodiment may have between about 8 and about 12 carbon atoms, such as about 8 to about 10 carbon atoms in each of the alkyl groups.
[0039] Examples of dimethyldialkylammonium compounds include dimethyldioctylammonium compounds such as dimethyldioctylammonium chloride, dimethyldidecylammonium compounds such as dimethyldidecylammonium chloride, etc. Mixtures of dimethyldialkylammonium compounds can also be used, and other anions such as those mentioned above can also be used. Commercially available dimethyldialkylammonium compounds include, for example, compositions marketed and sold by Arxada AG under the trade names BARDAC®, BARDAP®, BARQUAT®, or CARBOQUAT®.
[0040] Examples of such commercially available dimethyldialkylammonium compounds include dioctyldimethylammonium chloride (available from Arxada AG as Bardac® LF and LF-80), octyldecyldimethylammonium chloride (available as a mixture of octyldecyldimethylammonium chloride, dioctyldimethylammonium chloride and didecyldimethylammonium chloride from Arxada AG as Bardac® 2050 and 2080), didecyldimethylammonium chloride (available from Arxada AG as Bardac® 2250 and 2280), decylisononyldimethylammonium chloride (available from Arxada AG as Bardac® 21), diisodecyldimethylammonium chloride (available from Stepan Co., Northfield, Ill. as BTC 99), and any combination of any of the foregoing.
[0041] Preferably, the quaternary ammonium compound is selected from the group consisting of didecyldimethylammonium chloride, benzalkonium chloride, alkyldimethylbenzylammonium chloride (ADBAC), and combinations thereof. More preferably, the quaternary ammonium compound is alkyldimethylbenzylammonium chloride (Barquat® BAC-50).
[0042] The quaternary ammonium compound may be included in the end-use formulation in an amount up to about 0.2% by weight based on the total weight of the end-use formulation, depending on the particular quaternary ammonium compound. In certain embodiments, the end-use formulation may contain from about 0.1% to about 0.05% by weight based on the weight of the end-use formulation.
[0043] Exemplary pyrone compounds that can be used as preservatives in the present invention include, for example, dehydroacetic acid and its salts (e.g., sodium dehydroacetate). The pyrone compounds may be used in an amount of up to about 1.0% by weight, based on the total weight of the end-use formulation. In some embodiments, one or more pyrone compounds may be used in an amount of up to about 0.6% by weight. Preferably, the pyrone compound is selected from dehydroacetic acid or a salt thereof. More preferably, the pyrone compound is selected from dehydroacetic acid, sodium dehydroacetate, and combinations thereof. Even more preferably, the pyrone compound is dehydroacetic acid.
[0044] One or more urea compounds can be used as preservatives in certain embodiments.Exemplary urea compounds include, for example, 3-(4-chlorophenyl)-1-(3,4-dichlorophenyl)urea (triclocarban), 1,1'-methylenebis{3-[4-(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]urea}, and N-(hydroxymethyl)-N-(dihydroxymethyl-1,3-dioxo-2,5-imidazolinidyl-4)-N'-(hydroxymethyl)urea.These compounds are typically used in amounts up to about 0.5% by weight of the end-use formulation.
[0045] Exemplary imidazole compounds that can be used as preservatives in the present invention include, for example, 1-(4-chlorophenoxy)-1-(imidazol-1-yl)-3,3-dimethylbutan-2-one), 1,3-bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione. In some embodiments, one or more urea compounds may be included in an amount up to about 0.5% by weight of the end-use formulation.
[0046] In some embodiments, the preservative may include one or more isothiazolinones. Exemplary isothiazolinones include, for example, 5-chloro-2-methyl-isothiazol-3-one (chloromethylisothiazol-3-one), 2-methyl-isothiazol-3-one (methylisothiazol-3-one), benzisothiazolinone (BIT), 2-butyl-1,2-benzisothiazolin-3-one (BBIT), and mixtures thereof. In certain embodiments, one or more isothiazolinones may be used in an amount up to about 0.01% by weight of the end-use formulation. Preferably, the isothiazolinone is selected from benzisothiazolinone (BIT), 2-butyl-1,2-benzisothiazolin-3-one (BBIT), and combinations thereof.
[0047] More preferably, the isothiazolinone is benzisothiazolinone (BIT).
[0048] In yet another embodiment, the preservative can be an amine compound, such as a triamine compound. Suitable triamine compounds include, but are not limited to, those having the formula (2): [ka] In the formula, R is a substituted or unsubstituted C8-C 18 Alkyl, C8-C 18 Alkenyl, C8-C 18 Alkynyl, or C8-C 18 R is cycloalkyl or aryl, and R is optionally interrupted by one or more heteroatoms.
[0049] As used herein, the term "substituted" refers to one or more of a halogen (such as F, Cl, I, or Br), a heteroatom group, a C8-C 18 Alkyl, C8-C 18 Alkenyl, C8-C 18 Alkynyl, C8-C 18 Cycloalkyl, aryl, or carbonyl-containing C8-C 18Alkyl, C8-C 18 Alkenyl, or C8-C 18 Includes compounds substituted with alkynyl groups (such as ketones, esters, ethers, carbonates, or carboxylates).
[0050] Suitable heteroatoms include, but are not limited to, O, N, P, and S.
[0051] Suitable heteroatom groups include, but are not limited to, -NH2, -NO2, -SO2, -SO3, -PO3, ═O, and -OH.
[0052] The substituent R is preferably an unsubstituted C-C 18 Alkyl, C8-C 18 Alkenyl, C8-C 18 Alkynyl, C8-C 18 cycloalkyl, or aryl. Preferred triamines include, but are not limited to, N,N-bis(3-aminopropyl)-dodecylamine, bis(3-aminopropyl)octylamine, and N,N-bis(3-aminopropyl)-octylamine available as Lbac®12 from Arxada AG.
[0053] Another suitable amine compound is dicarboxymethylalanine trisodium.
[0054] Preferably, the amine compound is selected from N,N-bis(3-aminopropyl)-dodecylamine and dicarboxymethylalanine trisodium.
[0055] Amine preservatives may generally be included in amounts up to about 2% by weight of the end-use formulation, particularly from about 50 ppm to about 200,000 ppm, such as from about 50 ppm to about 500 ppm.
[0056] In one embodiment, the preservative can be a carbamate compound.Suitable carbamate compounds that can be used as preservative include iodopropynyl alkyl carbamates, such as 3-iodo-2-propynyl butyl carbamate (IPBC).Preferably, the carbamate compound is 3-iodo-2-propynyl butyl carbamate (IPBC).
[0057] In one embodiment, the preservative may be a guanidine compound.Suitable guanidine compounds that can be used as preservative include polymeric guanidine compounds, such as oligomeric or polymeric biguanide compounds.Suitable guanidine compounds include polyhexamethylene guanidine (PHMG), poly(hexamethylene) biguanide (PHMB), and polyaminopropyl biguanide (PAPB).Preferably, the guanidine compound is poly(hexamethylene) biguanide (PHMB).
[0058] Other ingredients that may be used as preservatives include dibromohexamidine and its salts, thiomersal, phyenyl mercury salts, hexetidine, 2-bromo-2-nitropropane-1,3-diol, 5-bromo-5-nitro-1,3-dioxane, polyhexamethylene biguanide or its salts, hexamethylenetetramine, methenamine 3-chloroallylochloride, 2-chloroacetamide, chlorhexidine and its digluconate or diacetate ester and its dihydrochloride salt, 4,4-dimethyl,1,3-oxazolidine, glutaraldehyde, 5-ethyl-3,7-dioxa-1-azabicyclooctane, sodium hydroxymethylglycinate, 3-iodo-2-propynyl butylcarbamate (IPBC), and ethyl lauroyl arginate. In certain embodiments, these ingredients may be included in amounts up to about 0.5% by weight of the end-use formulation.
[0059] In addition, the preservative may be a single preservative, may be a mixture of two or more preservatives from a single type of preservative, or may be a mixture of two or more different types of preservatives.
[0060] In one embodiment, the preservative is selected from the group consisting of phenoxyethanol, N,N-bis(3-aminopropyl)dodecylamine, didecyldimethylammonium chloride, sodium benzoate, benzoic acid, lactic acid, sodium lactate, benzyl alcohol, benzisothiazolinone, sorbic acid, potassium sorbate, 3-iodo-2-propynyl butylcarbamate (IPBC), dehydroacetic acid, sodium dehydroacetate, levulinic acid, sodium levulinate, sodium pyrithione, dicarboxymethylalanine trisodium, 2-butyl-1,2-benzisothiazolin-3-one, benzalkonium chloride, alkyldimethylbenzylammonium chloride (ADBAC), 2-hydroxypyridine-N-oxide, poly(hexamethylene) biguanide, and combinations thereof.
[0061] In one embodiment, the preservative is selected from the group consisting of sodium benzoate, benzoic acid, potassium sorbate, 3-iodo-2-propynyl butylcarbamate (IPBC), phenoxyethanol, bis(3-aminopropyl)dodecylamine, didecyldimethylammonium chloride, lactic acid, sodium lactate, benzyl alcohol, benzisothiazolinone, sorbic acid, dehydroacetic acid, sodium dehydroacetate, levulinic acid, sodium pyrithione, and combinations thereof.
[0062] Preferably, the preservative is selected from the group consisting of sodium benzoate, benzoic acid, potassium sorbate, sorbic acid, 3-iodo-2-propynyl butylcarbamate (IPBC), alkyldimethylbenzylammonium chloride (ADBAC), sodium pyrithione, lactic acid, sodium lactate, trisodium dicarboxymethylalanine, dehydroacetic acid, sodium dehydroacetate, benzisothiazolinone, 2-hydroxypyridine-N-oxide, poly(hexamethylene) biguanide, and combinations thereof.
[0063] More preferably, the preservative is selected from the group consisting of sodium benzoate, potassium sorbate, 3-iodo-2-propynyl butylcarbamate (IPBC), alkyldimethylbenzylammonium chloride (ADBAC), sodium pyrithione, lactic acid, trisodium dicarboxymethylalanine, dehydroacetic acid, benzisothiazolinone, 2-hydroxypyridine-N-oxide, poly(hexamethylene) biguanide, and combinations thereof.
[0064] Preferably, the preservative is selected from the group consisting of sodium benzoate, potassium sorbate, 3-iodo-2-propynyl butylcarbamate (IPBC), and combinations thereof.
[0065] The preservative composition of the present invention comprises at least one levulinic acid derivative selected from (a) levulinic acid esters, or (b) levulinic acid ketals, and combinations thereof. The levulinic acid esters and levulinic acid ketals that can be used in the present invention can be derived from (hemi)cellulose sources, etc.
[0066] Suitable levulinic acid esters include, but are not limited to, those having the formula (3): [ka] In the formula, R is C1 to C8 alkyl or C3 to C8 cycloalkyl.
[0067] As used herein, C1-C8 alkyl refers to a straight or branched chain saturated hydrocarbon group having 1 to 8 carbon atoms, including methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, heptyl, and octyl. Thus, C1-C8 alkyl includes C1, C2, C3, C4, C5, C6, C7 and C8 alkyl.
[0068] As used herein, C3-C8 cycloalkyl refers to a monocyclic saturated hydrocarbon group having 3 to 8 carbon ring members, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Thus, C3-C8 cycloalkyl is C3, C4, C5, C6, C7, and C8 cycloalkyl.
[0069] Thus, in one embodiment, the levulinic acid ester is 1~8 Alkyl levulinic acid ester, C 3~8 cycloalkyl levulinates, or combinations thereof.
[0070] In one embodiment, the levulinate ester is selected from the group consisting of methyl levulinate, ethyl levulinate, propyl levulinate, butyl levulinate, pentyl levulinate, and combinations thereof. Preferably, the levulinate ester is ethyl levulinate, butyl levulinate, or combinations thereof. In one preferred embodiment, the levulinate ester is ethyl levulinate. In one preferred embodiment, the levulinate ester is butyl levulinate.
[0071] The at least one levulinic acid derivative may be a levulinic acid ketal instead of, or in addition to, a levulinic acid ester.
[0072] In one embodiment, the levulinic acid ketal is selected from the group consisting of ethyl-3-(2,4-dimethyl-1,3-dioxolan-2-yl)propanoate, ethyl-3-[4-(hydroxymethyl)-2-methyl-1,3-dioxolan-2-yl]propanoate, and combinations thereof.
[0073] In one embodiment, the preservative is sodium benzoate and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is potassium sorbate and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is 3-iodo-2-propynyl butylcarbamate (IPBC) and the levulinic acid derivative is butyl levulinate.
[0074] In one embodiment, the preservative is phenoxyethanol and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is N,N-bis(3-aminopropyl)dodecylamine and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is didecyldimethylammonium chloride and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is sodium benzoate and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is benzoic acid and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is lactic acid and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is sodium lactate and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is benzyl alcohol and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is benzisothiazolinone and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is sorbic acid and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is potassium sorbate and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is 3-iodo-2-propynyl butylcarbamate (IPBC) and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is dehydroacetic acid and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is sodium dehydroacetate and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is levulinic acid and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is sodium levulinate and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is sodium pyrithione and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is dicarboxymethylalanine trisodium and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is 2-butyl-1,2-benzisothiazolin-3-one and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is benzalkonium chloride and the levulinic acid derivative is ethyl levulinate.In one embodiment, the preservative is alkyldimethylbenzylammonium chloride (ADBAC) and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is 2-hydroxypyridine-N-oxide and the levulinic acid derivative is ethyl levulinate. In one embodiment, the preservative is poly(hexamethylene) biguanide and the levulinic acid derivative is ethyl levulinate.
[0075] In one embodiment, the preservative is phenoxyethanol and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is N,N-bis(3-aminopropyl)dodecylamine and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is didecyldimethylammonium chloride and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is sodium benzoate and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is benzoic acid and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is lactic acid and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is sodium lactate and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is benzyl alcohol and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is benzisothiazolinone and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is sorbic acid and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is potassium sorbate and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is 3-iodo-2-propynyl butylcarbamate (IPBC) and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is dehydroacetic acid and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is sodium dehydroacetate and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is levulinic acid and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is sodium levulinate and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is sodium pyrithione and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is dicarboxymethylalanine trisodium and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is 2-butyl-1,2-benzisothiazolin-3-one and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is benzalkonium chloride and the levulinic acid derivative is butyl levulinate.In one embodiment, the preservative is alkyldimethylbenzylammonium chloride (ADBAC) and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is 2-hydroxypyridine-N-oxide and the levulinic acid derivative is butyl levulinate. In one embodiment, the preservative is poly(hexamethylene) biguanide and the levulinic acid derivative is butyl levulinate.
[0076] The weight ratio of the at least one levulinic acid derivative to the preservative can vary depending on a variety of factors. For example, the weight ratio of the at least one levulinic acid derivative to the preservative can depend on the composition of the final product, the microorganisms to be controlled, the particular at least one levulinic acid derivative and preservative used, the final properties of the product, etc.
[0077] The weight ratio of the at least one levulinic acid derivative to the preservative may generally be in the range of about 10,000:1 to 1:100, such as 8000:1 to 1:50. For example, the weight ratio of the at least one levulinic acid derivative to the preservative may generally be in the range of about 10:1 to 1:100, such as 9:1 to 1:90, such as 8:1 to 1:80, such as 7:1 to 1:70, such as 6:1 to 1:60, such as 5:1 to 1:50.
[0078] In many applications, only a small amount of the at least one levulinic acid derivative is needed to enhance the effectiveness of the preservative. For example, in one embodiment, the preservative is present in an amount greater than the at least one levulinic acid derivative.
[0079] In one embodiment, the preservative is sodium benzoate, and the at least one levulinic acid derivative and sodium benzoate are included in the preservative composition in a weight ratio of 10:1 to 1:100, preferably 5:1 to 1:50. In one embodiment, the preservative is sodium benzoate, and the at least one levulinic acid derivative and sodium benzoate are included in the preservative composition in a weight ratio of 100:1 to 1:100, preferably 50:1 to 1:50.
[0080] In one embodiment, the preservative is benzoic acid or a salt thereof, and the at least one levulinic acid derivative and the benzoic acid or a salt thereof are contained in the preservative composition in a weight ratio of 100:1 to 1:100, preferably 50:1 to 1:50.
[0081] In one embodiment, the preservative is potassium sorbate, and the at least one levulinic acid derivative and potassium sorbate are included in the preservative composition in a weight ratio of 10:1 to 1:100, preferably 1:1 to 1:50. In one embodiment, the preservative is potassium sorbate, and the at least one levulinic acid derivative and potassium sorbate are included in the preservative composition in a weight ratio of 500:1 to 1:10.
[0082] In one embodiment, the preservative is 3-iodo-2-propynyl butylcarbamate (IPBC), and the at least one levulinic acid derivative and the 3-iodo-2-propynyl butylcarbamate (IPBC) are included in the preservative composition in a weight ratio of 25:1 to 1:2, preferably 25:1 to 1:5.
[0083] In one embodiment, the preservative is alkyldimethylbenzylammonium chloride (ADBAC), and the at least one levulinic acid derivative and alkyldimethylbenzylammonium chloride (ADBAC) are included in the preservative composition in a weight ratio of 8000:1 to 500:1, preferably 7000:1 to 700:1.
[0084] In one embodiment, the preservative is sodium pyrithione, and the at least one levulinic acid derivative and the sodium pyrithione are included in the preservative composition in a weight ratio of 8000:1 to 5:1, preferably 7000:1 to 5:1.
[0085] In one embodiment, the preservative is levulinic acid, and the at least one levulinic acid derivative and levulinic acid are present in the preservative composition in a weight ratio of 50:1 to 1:50, preferably 25:1 to 1:25.
[0086] In one embodiment, the preservative is phenoxyethanol, and the at least one levulinic acid derivative and phenoxyethanol are included in the preservative composition in a weight ratio of 50:1 to 1:100, preferably 10:1 to 1:25.
[0087] In one embodiment, the preservative is lactic acid or a salt thereof, and the at least one levulinic acid derivative and the lactic acid or a salt thereof are contained in the preservative composition in a weight ratio of 60:1 to 1:5, preferably 40:1 to 1:4.
[0088] In one embodiment, the preservative is sodium lactate, and the at least one levulinic acid derivative and sodium lactate are present in the preservative composition in a weight ratio of 60:1 to 1:5, preferably 40:1 to 1:4.
[0089] 10. The preservative composition according to claim 1, wherein the preservative is dicarboxymethylalanine trisodium, and the at least one levulinic acid derivative and dicarboxymethylalanine trisodium are contained in the preservative composition in a weight ratio of 5:1 to 1:5, preferably 3:1 to 1:3.
[0090] In one embodiment, the preservative is benzyl alcohol, and the at least one levulinic acid derivative and the benzyl alcohol are present in the preservative composition in a weight ratio of 50:1 to 1:100, preferably 10:1 to 1:10.
[0091] In one embodiment, the preservative is sorbic acid or a salt thereof, and the at least one levulinic acid derivative and the sorbic acid or a salt thereof are included in the preservative composition in a weight ratio of 25:1 to 1:5, preferably 10:1 to 1:2. In one embodiment, the preservative is sorbic acid or a salt thereof, and the at least one levulinic acid derivative and the sorbic acid or a salt thereof are included in the preservative composition in a weight ratio of 500:1 to 1:10.
[0092] In one embodiment, the preservative is dehydroacetic acid or a salt thereof, and the at least one levulinic acid derivative and dehydroacetic acid or a salt thereof are contained in the preservative composition in a weight ratio of 25:1 to 1:5, preferably 10:1 to 1:2. In one embodiment, the preservative is dehydroacetic acid or a salt thereof, and the at least one levulinic acid derivative and dehydroacetic acid or a salt thereof are contained in the preservative composition in a weight ratio of 300:1 to 1:10, preferably 250:1 to 1:8. In one embodiment, the preservative is sodium dehydroacetate, and the at least one levulinic acid derivative and sodium dehydroacetate are contained in the preservative composition in a weight ratio of 300:1 to 1:10, preferably 250:1 to 1:8.
[0093] In one embodiment, the preservative is a benzisothiazolinone, and the at least one levulinic acid derivative and the benzisothiazolinone are included in the preservative composition in a weight ratio of 200:1 to 1:10, preferably 150:1 to 1:5.
[0094] In one embodiment, the preservative is 2-hydroxypyridine-N-oxide, and the at least one levulinic acid derivative and the 2-hydroxypyridine-N-oxide are present in the preservative composition in a weight ratio of 75:1 to 1:1, preferably 60:1 to 1:1.
[0095] In one embodiment, the preservative is poly(hexamethylene) biguanide, and the at least one levulinic acid derivative and the poly(hexamethylene) biguanide are present in the preservative composition in a weight ratio of 800:1 to 5:1, preferably 700:1 to 7:1.
[0096] A variety of different microorganisms can be controlled according to the present invention. For example, the preservative composition of the present invention can control gram-positive bacteria, gram-negative bacteria, etc. In addition to bacteria, the preservative composition of the present invention can also kill and control the growth of a variety of other microorganisms, such as fungi, viruses, spores, yeasts, mycobacteria, etc.Non-limiting examples of specific microorganisms that may be controlled in accordance with the present invention include Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, Serratia marcescens, Salmonella enteritidis, Neisseria gonorrhoeae, Escherichia coli, Enterococcus hirae, Acinetobacter baumannii, Listeria monocytogenes, Enterobacer gergoviae, Klebsiella pneumoniae, Burkholderia cepacia, Pseudomonas putida, Kocuria rhizophila, Candida albicans, and the like. albicans, Saccharomyces cerevisiae, Aspergillus brasiliensis, Penicillium funiculosum, Eupenicillium levitum, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium perfringens, Mycobacterium tuberculosis, Mycobacterium terrae, Mycobacterium avium avium), poliovirus, adenovirus, norovirus, vaccinia virus, influenza virus, hepatitis B virus, human immunodeficiency virus, human papillomavirus, or mixtures thereof. Preferably, the microorganism is selected from Aspergillus braziliens, Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Candida albicans, and mixtures thereof.
[0097] The present invention further relates to an end use formulation comprising the preservative composition according to the present invention. The end use formulation may have a pH of 4 or more, a pH of 5 or more, a pH of 6 or more, or a pH of 7 or more. Thus, the end use formulation may have a pH of 4 or more, 4.5 or more, 5 or more, 5.5 or more, 6 or more, 6.5 or more, 7 or more, 7.5 or more, 8 or more, 8.5 or more, 9 or more, 9.5 or more, or 10 or more. In one embodiment, the end use formulation has a pH of 4-9, preferably 6-8. In one embodiment, the end use formulation has a pH of 6-9, preferably 7-8.
[0098] In one embodiment, the preservative is present in the end use formulation in an amount of 1% or less by weight, such as 0.5% or less by weight based on the weight of the end use formulation.
[0099] In general, the preservative composition of the present invention can be incorporated into any number of different end-use formulations or products. As used herein, "end-use formulation" is intended to include personal care products, cosmetics, home care products, and health and hygiene products. In one embodiment, the end-use formulation is a personal care product. For example, the personal care product may include products such as face creams, makeup removers, mascaras, or cosmetic formulations including wet wipes. Personal care products also include shampoos, conditioners, skin lotions, or liquids for any personal care wet wipe applications. Personal care products may include any products for topical application to the skin or hair of a user. When the preservative composition of the present invention is incorporated into an end-use formulation, the preservative composition provides effective broad-spectrum preservative activity over a wide pH range, specifically at pH 4 or higher, pH 5 or higher, or pH 6 or higher, such as pH 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10 or higher. For example, in certain embodiments, the end use formulation, e.g., a personal care product, may have a pH in the range of about 4 to 10, e.g., about 6 to 10, e.g., about 6 to about 8, particularly about 6 to about 8, or about 7 to about 8. Thus, the preservative composition of the present invention may exhibit broad antimicrobial coverage in end use formulations across a wide range of end use formulations having a variety of pHs.
[0100] In an embodiment, the preservative composition of the present invention may have a pH in the range of about 3 to about 9, such as about 4 to about 9, for example about 5 to about 8, particularly about 6 to about 8 or about 7 to about 8.
[0101] End-use formulations, such as personal care products, may include a base formulation to which the preservative composition of the present invention is added. The base formulation may contain a number of different ingredients, depending on the end-use application. The end-use formulation may contain, for example, solvents, surfactants, emulsifiers, consistency factors, conditioners, emollients, skin care ingredients, moisturizers, thickeners, humectants, fillers, antioxidants, other preservatives, active ingredients, especially dermatological active ingredients, fragrances, and the like, as well as mixtures thereof. Active ingredients referred to herein include, for example, anti-inflammatory agents, antibacterial agents, antifungal agents, and the like. Active ingredients suitable for topical application are particularly preferred.
[0102] Suitable surfactants include alkyl sulfates, such as sodium lauryl sulfate, ammonium lauryl sulfate, sodium cetearyl sulfate, alkyl sulfoacetates, such as sodium lauryl sulfoacetate, alkyl ether sulfates, such as sodium laureth sulfate, sodium trideceth sulfate, sodium oleth sulfate, ammonium laureth sulfate, alkyl ether sulfosuccinates, such as disodium laureth sulfosuccinate, alkyl glycosides, such as decyl glucoside, lauryl glucoside, , alkyl isethionate amphoteric compounds such as cocamidopropyl betaine, disodium cocoamphoacetate, sodium lauroamphoacetate, disodium lauroamphodiacetate, disodium cocoamphodiacetate, sodium lauroamphopropionate, disodium lauroamphodipropionate, potassium or ammonium salts of the aforementioned amphoteric compounds, capryl / capramidopropyl betaine, undecylenamidopropyl betaine, lauroamidopropyl betaine, and fatty alcohol polyglycol ethers.
[0103] Suitable emulsifiers include, for example, anionic substances as salts of fatty acids (e.g. sodium stearate or sodium palmitate), organic soaps (e.g. mono-, di- or triethanolaminoates), sulfated or sulfonated compounds (e.g. sodium lauryl sulfate or sodium cetylsulfonate), saponins, ramepones, cations as quaternary ammonium salts, nonionic substances as fatty alcohols, fatty acid esters with saturated or unsaturated fatty acids, polyoxyethylene esters or polyoxyethylene ethers of fatty acids, polymers from ethylene oxide and propylene oxide or propylene glycol, amphoteric compounds as phosphatides, proteins as gelatins, casein alkylamidobetaines, alkylbetaines and amphoglycinates, alkylphosphates, alkylpolyoxyethylenephosphates or the corresponding acids, silicone derivatives, such as alkyldimethiconecopolyols.
[0104] Suitable consistency agents include, for example, fatty alcohols or mixtures thereof with fatty acid esters, such as acetylated lanolin alcohol, aluminum stearate, carbomer, cetyl alcohol, glyceryl oleate, glyceryl stearate, glyceryl stearate (and) PEG 100 stearate, magnesium stearate, magnesium sulfate, oleic acid, stearic acid, stearyl alcohol, myristyl myristate, isopropyl palmitate, beeswax and its synthetic equivalents, carbomer, and the like. Suitable conditioners include, for example, alkylamidoammonium lactate, cetrimonium chloride and distearoylethylhydroxyethylmonium methosulfate and cetearyl alcohol, cetyl dimethicone, cetyl ricinoleate, dimethicone, laureth-23, laureth-4, polydecene, retinyl palmitate, quaternized protein hydrolysates, quaternized cellulose and starch derivatives, quaternized copolymers of acrylic or methacrylic acid or salts, quaternized silicone derivatives.
[0105] Suitable emollients include, for example, cetearyl isononanoate, cetearyl octanoate, decyl oleate, isooctyl stearate, cococaprylate / caprate, ethylhexyl hydroxystearate, ethylhexyl isononanoate, isopropyl isostearate, isopropyl myristate, oleyl oleate, hexyl laurate, mineral oil, PEG-75 lanolin, PEG-7 glyceryl cocoate, petrolatum, ozokerite cyclomethicone, dimethicone, dimethicone copolyol, dicaprylyl ether, butyrospermum parkii, buxus sinensis, canola, carnauba cera, copernicia cerifera, oenothera biennis, biennis, oil palm, prunus dulcis, squalane, zea mays, glycine soja, helianthus annuus, lanolin, hydrogenated castor oil, hydrogenated coconut oil, hydrogenated polyisobutene, sucrose cocoate, stearoxy dimethicone, lanolin alcohol, isohexadecane.
[0106] Suitable skin care ingredients include, for example, botanical extracts, bisabolol, anti-inflammatory agents, urea, allantoin, panthenol and panthenol derivatives, phytantriol, vitamins A, E, C, D, ceramides of animal or plant origin, lecithin, and the like.
[0107] Suitable humectants include, for example, butylene glycol, cetyl alcohol, dimethicone, dimyristyl tartrate, glucose glycereth-26, glycerin, glyceryl stearate, hydrolyzed milk protein, lactic acid, lactose and other sugars, laureth-8, lecithin, octoxyglycerin, PEG-12, PEG135, PEG-150, PEG-20, PEG-8, pentylene glycol, hexylene glycol, phytantriol, polyquaternium-39 PPG-20 methyl glucose ether, propylene glycol, sodium hyaluronate, sodium lactate, sodium PCA, sorbitol, succinoglycan, synthetic beeswax, tri-C14-15 alkyl citrate, and starch.
[0108] Suitable thickening agents include, for example, acrylates / steareth-20 methacrylate copolymer, carbomer, carboxymethyl starch, cera alba, dimethicone / vinyl dimethicone crosspolymer, propylene glycol alginate, hydroxyethyl cellulose, hydroxypropyl methylcellulose, silica, silica dimethyl silylate, xanthan gum, hydrogenated butylene / ethylene / styrene copolymer.
[0109] Suitable moisturizing agents include, for example, adipic acid, fumaric acid and its salts, benzoic acid and its salts, glycerin triacetate, sodium or magnesium lauryl sulfate, magnesium stearate, solid polyethylene glycols, polyvinylpyrrolidone, boric acid, mono-laurate or mono-palmitate, myristyl alcohol, cetyl alcohol, cetylstearyl alcohol, talcum, calcium or magnesium salts of higher fatty acids, mono-, di-, or triglycerides of higher fatty acids, polytetrafluoroethylene.
[0110] Suitable antioxidants include, for example, sulfites, such as sodium sulfite, tocopherol or a derivative thereof, ascorbic acid or a derivative thereof, citric acid, propyl galleate, chitosan glycolate, cysteine, N-acetylcysteine plus zinc sulfate, thiosulfates, such as sodium thiosulfate, polyphenols, and the like.
[0111] The formulations and compositions disclosed herein may further contain active ingredients such as antibacterial agents, anti-inflammatory agents, botanical extracts, bisabolol, panthenol, tocopherol, actives for anti-stinging, anti-irritation or anti-dandruff applications, or anti-aging agents such as retinol, melibiose, and the like. Other suitable active agents include, for example, Medicago officinalis, Actinidia sinensis, allantoin, Aloe barbadensis, Anona cherimolia, Anthemis nobilis, Arachis hypogaea, Arnica Montana, Avena sativa, beta carotene, bisabolol, Borago officinalis, butylenes glycol, Calendula officinalis, Camellia sinensis, camphor, Candida bombicola, and the like. bombicola, Caproyl Glycine, Carica papaya, Cornflower, Cetylpyridinium Chloride, Chamomilla recutita, Chenopodium quinoa, Chinchona succirubra, Chondrus crispus, Citrus aurantium dulcis, Citrus grandis, Citrus limonum, Cocos nucifera, Coffea arabica, Crataegus monogina, Cucumis melo melo), Dichlorophenylimidazoldioxolane, Enteromorpha compressa, Equisetum arbensearvense, Ethoxydiglycol, Ethyl Panthenol, Farnesol, Ferulic Acid, Fragaria chiloensis, Gentiana lutea, Ginkgo, Glycerin, Glyceryl Laurate, Licorice Root, Hamamelis virginiana, Heliotropin, Hydrogenated Palm Glycerides, Citrate, Hydrolyzed Castor Oil, Hydrolyzed Wheat Protein, Hypericum perforatum, Iris florentina, Juniperus communis, Lactis proteinum, Lactose, Lawsonia inermis, Linaleur, Linum usitatissimum usitatissimum, Lysine, Magnesium Aspartate, Magnifera indica, Malva sylvestris, Mannitol, Melaleuca alternifolia, Mentha piperita, Menthol, Menthyl Lactate, Mimosa tenuiflora, Nymphaea alba, Olaflur, Oryza sativa, Panthenol, Mineral Oil, PEG-20M, PEG-26 Jojoba Acid, PEG-26 Jojoba Alcohol, PEG-35 Castor Oil, PEG-40 Hydrogenated Castor Oil, PEG-60 Hydrogenated Castor Oil, PEG-8 Caprylic / Capric Acid, Persea Gratissima gratissima, Petrolatum, Potassium Aspartate, Potassium Sorbate, Propylene Glycol, Prunus amygdalus dulcis, Prunus armeniaca, Prunus persica, Retinyl Palmitate, Ricinus communis, Rosa caninacanina, Rosmarinus officinalis, Rubus idaeus, Salicylic Acid, Sambucus nigra, Sarcosine, Serenoa serrulata, Simmondsia sinensis, Sodium Carboxymethyl Betaglucan, Sodium Coil Amino Acids, Sodium Hyaluronate, Sodium Palmitoyl Praline, Stearoxytrimethylsilane, Stearyl Alcohol, Sulfated TEA-Ricinoleate, Talc, Thymus vulgaris, Tilia cordata, Tocopherol, Tocopheryl Acetate, Trideceth-9, Triticum vulgare, Tyrosine, Undecylenoyl Glycine, Urea, Vaccinium Myrtillus myrtillus), valine, zinc oxide, and zinc sulfate.
[0112] The preservative compositions of the present invention can be used in emulsions (both oil-in-water and water-in-oil), aqueous solutions, PIT (phase inversion temperature) emulsions, oil-based solutions, foaming cosmetic formulations (foams), and so-called multiple emulsions, e.g. triple emulsions (such as water / oil / water emulsions).
[0113] The preservative compositions of the present invention can also be added to end-use formulations such as creams, gels, liquids or lotions. They can be used in hair care products such as shampoos, hair conditioners, hair dyes, hair tonics, hair gels, hair dressings, hair grooming aids and other hair care preparations, shaving applications such as shaving creams, aftershave lotions and other shaving applications, personal cleaners for body and hands such as liquid bath soaps and detergents, fragrance preparations such as perfumes, after bath splashes and other similar fragrance preparations, skin care products such as moisturizers, creams, and lotions and other similar skin care products, and make-up products such as mascara, base foundation, make-up removal products, sun care products, indoor tanning products and other similar personal care products. In certain embodiments, the preservative compositions disclosed herein can be incorporated into formulations used to saturate wipes used for personal cleaning and hygiene (e.g., baby wipes, wet toilet wipes, make-up removal wipes, exfoliating wipes). The preservative compositions can also be used in other formulations where preservatives are required. All of the above exemplified products are intended to be understood as end-use formulations in the context of the present invention.
[0114] In some embodiments, the preservative composition of the present invention may be added to the end-use formulation in an amount of 0.01% to about 5% by weight, based on the total weight of the end-use formulation. More specifically, in some embodiments, the preservative composition is added in an amount of 0.1% to about 3% by weight, based on the total weight of the end-use formulation. The amount of the preservative composition added may depend on the preservative selected.
[0115] The present invention further relates to the use of a preservative composition according to the invention for increasing its effectiveness against microorganisms compared to an equivalent amount of a preservative not comprising at least one levulinic acid derivative.
[0116] The present invention further relates to the use of at least one levulinic acid derivative selected from (a) a levulinic acid ester, or (b) a levulinic acid ketal, and combinations thereof, to increase the effectiveness of at least one preservative against microorganisms compared to an equivalent amount of the preservative without the at least one levulinic acid derivative.
[0117] In one embodiment, the effectiveness against microorganisms is increased at pH 4-9 or higher compared to an equivalent amount of the preservative at pH 4-9 without the at least one levulinic acid derivative. Preferably, the effectiveness against microorganisms is increased at pH 6-8 or higher compared to an equivalent amount of the preservative at pH 6-8 without the at least one levulinic acid derivative.
[0118] In one embodiment, the efficacy is increased by at least a 0.5 log decrease. In one embodiment, the efficacy is increased by at least a 1.0 log decrease.
[0119] The present invention further relates to a method for preventing microbial spoilage of an end-use formulation, comprising adding a preservative composition according to the present invention to the end-use formulation, in one embodiment, the end-use formulation has a pH of 4 or greater, preferably a pH of 6 or greater.
[0120] It is clear to those skilled in the art that these embodiments and items depict only examples of multiple possibilities. Therefore, the embodiments shown herein should not be understood to form a limitation of these features and configurations. Any possible combination and configuration of the described features may be selected according to the scope of the present invention. All embodiments and preferred embodiments described herein in relation to a certain aspect of the present invention (e.g., the preservative composition of the present invention) apply equally to all other aspects of the present invention, such as the end-use formulation, use or method according to the present invention.
[0121] The invention is further illustrated by the following examples in which all parts and percentages are by weight unless otherwise indicated. EXAMPLES
[0122] [Example 1] Preservative effect of butyl levulinate in combination with sodium benzoate in sterile distilled water ("SDW", pH 7). The pH was adjusted using sodium hydroxide and citric acid monohydrate.
[0123] <Method> In the examples below, the following test organisms were used: Pseudomonas aeruginosa ATCC 9027 Aspergillus braziliensis ATCC 16404
[0124] <Test organism preparation> Inoculum growth conditions
[0125] [Table 1]
[0126] Bacteria were harvested and prepared in diluent (sterile distilled water) to a concentration of 1.0 × 10 6 ~5.0×10 6 A final concentration of cfu / ml was obtained.
[0127] Yeast strains were harvested and prepared in diluent (sterile distilled water) to give a concentration of 1.0 × 10 5 ~1.0×10 6 A final concentration of cfu / ml was obtained.
[0128] Mold strain spores were harvested (sterile distilled water + 0.05% polysorbate 80) and treated to remove fungal hyphae. Mold strain spores were prepared in diluent (sterile distilled water) to a concentration of 1.0 × 10 5 ~1.0×10 5 A final concentration of cfu / ml was obtained.
[0129] <Test sample preparation> Samples were prepared for testing according to the table below.
[0130] [Table 2]
[0131] <Test procedure> The preservative efficacy test began on day 0 (t=0). Each sample was inoculated with a known concentration of microorganism at t=0. Each inoculated sample was then mixed until a homogenous mixture was obtained. The inoculated samples were stored at 22.5±2.5°C in the dark throughout the test period.
[0132] Evaluation of antibacterial activity At the designated contact time (t=7) of 7 days, the test samples were inactivated by adding a 0.1 ml aliquot of the test sample to 0.9 ml of the appropriate neutralizing broth. The solution was allowed to stand for 15 minutes. Subsequent dilutions were prepared by serial dilutions of 0.1 ml into 0.9 ml of neutralizing broth. Bacteria were inactivated at 10 -4 Serial dilutions of the fungus were performed at 10 -3 Serial dilutions were made.
[0133] Drop Plate Method Each serial dilution was mixed thoroughly and 25 μl drops were aliquoted onto the surface of pre-prepared agar plates. Plates were prepared in six replicates for each sample dilution.
[0134] The agar plates were allowed to dry, then inverted and incubated under conditions appropriate for the test microorganism.
[0135] CFU / ml was calculated taking into account the dilution factor. Colonies from the incubated plates were counted using a lower count limit of <10 CFU / ml and an upper count limit of >330 CFU / ml. The lower and upper limits for drop plating were only used on the highest and lowest dilution factor plates.
[0136] <Result>
[0137] [Table 3]
[0138] Enhancement of sodium benzoate was observed with butyl levulinate against bacteria and molds in a sterile distilled water matrix at pH 7.
[0139] [Example 2] Preservative effect of butyl levulinate in combination with sodium benzoate in sterile distilled water (pH 8). The pH was adjusted using sodium hydroxide and citric acid monohydrate.
[0140] <Method> The test organisms were prepared and the method was carried out according to the protocol of Example 1.
[0141] <Result>
[0142] [Table 4]
[0143] Enhancement of sodium benzoate was observed with butyl levulinate against bacteria and molds in a sterile distilled water matrix at pH 8.
[0144] [Example 3] Preservative effect of butyl levulinate in combination with IPBC in sterile distilled water (pH 7). The pH was adjusted using sodium hydroxide and citric acid monohydrate.
[0145] <Method> The test organisms were prepared and the method was carried out according to the protocol of Example 1.
[0146] <Result>
[0147] [Table 5]
[0148] IPBC enhancement was observed by butyl levulinate against mold in a sterile distilled water matrix at pH 7.
[0149] [Example 4] Preservative effect of butyl levulinate in combination with potassium sorbate in sterile distilled water (pH 7). The pH was adjusted using sodium hydroxide and citric acid monohydrate.
[0150] <Method> The test organisms were prepared and the method was carried out according to the protocol of Example 1.
[0151] <Result>
[0152] [Table 6] TIFF2024544850000010.tif91168
[0153] [Example 5] Preservative effect of butyl levulinate in combination with potassium sorbate in sterile distilled water (pH 8). The pH was adjusted using sodium hydroxide and citric acid monohydrate.
[0154] <Method> The test organisms were prepared and the method was carried out according to the protocol of Example 1.
[0155] <Result>
[0156] [Table 7]
[0157] [Example 6] The synergistic preservative effect of butyl levulinate in combination with sodium benzoate in Frame Formulation 1 (SLES+CapB shampoo formulation having a pH of 7) was tested.
[0158] <Method> In the examples below, the following test organisms were used: Aspergillus braziliensis ATCC 16404
[0159] <Test organism preparation> Inoculum growth conditions
[0160] [Table 8]
[0161] Mold strain spores were harvested (sterile distilled water + 0.05% polysorbate 80) and treated to remove fungal hyphae. Mold strain spores were prepared in diluent (sterile distilled water) to a concentration of 1.0 × 10 7 ~1.0×10 7 A final concentration of cfu / ml was obtained.
[0162] <Test sample preparation> Samples were prepared for testing according to the table below.
[0163] [Table 9]
[0164] <Test procedure> The preservative efficacy test began on day 0 (t=0). Each sample was inoculated with a known concentration of microorganism at <1% volume at t=0. Each inoculated sample was then mixed until a homogenous mixture was obtained. The inoculated samples were stored at 22.5±2.5°C in the dark throughout the test period.
[0165] Evaluation of antibacterial activity At the designated contact times (t=7, 14, 28), the test samples were inactivated by adding a 1 ml aliquot of the test sample to 9 ml of the appropriate neutralizing broth. The solution was allowed to stand for 15 minutes. Subsequent dilutions were prepared by serial dilutions of 1 ml into 9 ml of neutralizing broth. All samples were diluted at 10 -3 Serial dilutions were made.
[0166] Pour plate method Each serial dilution was mixed thoroughly and 1 ml was aliquoted into sterile Petri dishes. 20-25 ml of the appropriate agar was poured into each Petri dish. Plates were prepared in duplicate for each sample dilution.
[0167] The agar plates were allowed to dry, then inverted and incubated under conditions appropriate for the test microorganism.
[0168] CFU / ml was calculated taking into account the dilution factor. Colonies from the incubated plates were counted using a lower count limit of <10 CFU / ml and an upper count limit of >330 CFU / ml.
[0169] <Result> Log reduction was calculated for each experiment by the difference in recovery between the test formulation and the initial stock concentration.
[0170] [Table 10]
[0171] Enhancement of sodium benzoate was observed with butyl levulinate against A. brasiliensis in Frame Formulation 1 (SLES+CapB shampoo formulation) having a pH of 7.
[0172] [Example 7] The synergistic activity of ethyl and butyl levulinate and preservatives is demonstrated as part of a two-component composition.
[0173] A wide range of concentrations was tested against Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Candida albicans.
[0174] The lowest concentration of each mixture or single compound that prevented observable levels of growth was determined as the minimum inhibitory concentration (MIC) value.
[0175] Serial dilutions of each mixture or single compound were prepared. The microorganisms were inoculated into the media, i.e., nutrient medium (bacteria) or malt extract medium (yeast). The final concentration of the microorganisms in the media was approximately 10 5~6 The inoculated medium was introduced into each of the serial dilutions at a 1:1 ratio and incubated at 30±1°C for 24-48 hours.
[0176] The MIC of each mixture was compared to the MIC of each single compound alone.
[0177] The synergistic effect is determined using the Kull equation (FC Kull et al., "Mixtures of Quaternary Ammonium Compounds and Long-chain Fatty Acids as Antifungal Agents", Appl Microbiol. 1961 Nov;9(6):538-541) and the synergy index (SI) is calculated according to the following formula: SI=Qa / QA+Qb / QB During the ceremony, QA = the concentration (ppm) of compound A that acted alone to produce the endpoint; Qa = the concentration of compound A in the mixture that produced the endpoint (ppm); QB = the concentration (ppm) of compound B that acted alone to produce the endpoint; Qb = the concentration of compound B in the mixture that gave the endpoint (ppm).
[0178] In this study, the endpoint is determined by the MIC.
[0179] Synergy is demonstrated by an SI value less than 1. Additivity is demonstrated by an SI value equal to 1. Antagonism is demonstrated by an SI value greater than 1.
[0180] The initial concentrations of each single compound were prepared as follows:
[0181] [Table 11]
[0182] (1) Synergistic interactions between ethyl levulinate and preservatives
[0183] [Table 12] TIFF2024544850000017.tif226168TIFF2024544850000018.tif224168TIFF2024544850000019.tif226168
[0184] (2) Synergistic interactions between butyl levulinate and preservatives
[0185] [Table 13] TIFF2024544850000021.tif138168TIFF2024544850000022.tif190168TIFF20245448500 00023.tif228168TIFF2024544850000024.tif220168TIFF2024544850000025.tif135168
Claims
1. (i) at least one preservative; and (ii) at least one levulinic acid derivative selected from (a) a levulinic acid ester, or (b) a levulinic acid ketal, and combinations thereof; Including, A preservative composition, wherein the at least one levulinic acid derivative is present in an amount sufficient to enhance the effectiveness of the preservative as compared to the preservative alone.
2. 2. The preservative composition of claim 1, wherein the at least one levulinic acid derivative is present in an amount sufficient to enhance the effectiveness of the preservative at a pH of 4 to 9, preferably 6 to 8, compared to the preservative alone.
3. 3. The preservative composition of claim 1 or 2, wherein the preservative is selected from acid compounds and their salts, aldehydes, phenolic compounds, sulfites, iron chelating agents, aromatic alcohols, quaternary ammonium compounds, pyrone compounds, urea compounds, guanidine compounds, pyridine compounds, imidazole compounds, isothiazolinone compounds, amine compounds, carbamate compounds, or any combination thereof.
4. 4. The preservative composition of any one of claims 1 to 3, wherein the preservative is selected from the group consisting of phenoxyethanol, N,N-bis(3-aminopropyl)dodecylamine, didecyldimethylammonium chloride, sodium benzoate, benzoic acid, lactic acid, sodium lactate, benzyl alcohol, benzisothiazolinone, sorbic acid, potassium sorbate, 3-iodo-2-propynyl butylcarbamate (IPBC), dehydroacetic acid, sodium dehydroacetate, levulinic acid, sodium levulinate, sodium pyrithione, dicarboxymethylalanine trisodium, 2-butyl-1,2-benzisothiazolin-3-one, benzalkonium chloride, alkyldimethylbenzylammonium chloride (ADBAC), 2-hydroxypyridine-N-oxide, poly(hexamethylene) biguanide, and combinations thereof.
5. 5. The preservative composition of any one of claims 1 to 4, wherein the preservative is selected from the group consisting of sodium benzoate, benzoic acid, potassium sorbate, sorbic acid, 3-iodo-2-propynyl butylcarbamate (IPBC), alkyldimethylbenzylammonium chloride (ADBAC), sodium pyrithione, lactic acid, sodium lactate, trisodium dicarboxymethylalanine, dehydroacetic acid, sodium dehydroacetate, benzisothiazolinone, 2-hydroxypyridine-N-oxide, poly(hexamethylene) biguanide, and combinations thereof.
6. The levulinic acid ester is 1~8 Alkyl levulinic acid ester, C 3~8 6. The preservative composition of claim 1, wherein the carboxylic acid ester is a cycloalkyl levulinic acid ester, a cycloalkyl levulinic acid ester, or a combination thereof.
7. 7. The preservative composition of any one of claims 1 to 6, wherein the levulinate ester is selected from the group consisting of methyl levulinate, ethyl levulinate, propyl levulinate, butyl levulinate, pentyl levulinate, and combinations thereof.
8. 8. The preservative composition of any one of claims 1 to 7, wherein the levulinic acid ester is ethyl levulinate, butyl levulinate, or a combination thereof.
9. 9. The preservative composition of any one of claims 1 to 8, wherein the levulinic acid ketal is selected from the group consisting of ethyl-3-(2,4-dimethyl-1,3-dioxolan-2-yl)propanoate, ethyl-3-[4-(hydroxymethyl)-2-methyl-1,3-dioxolan-2-yl]propanoate, and combinations thereof.
10. 10. The preservative composition according to any one of claims 1 to 9, wherein the preservative is benzoic acid or a salt thereof, preferably the salt of benzoic acid is sodium benzoate, and the at least one levulinic acid derivative and benzoic acid or a salt thereof are contained in the preservative composition in a weight ratio of 50:1 to 1:
50.
11. 10. The preservative composition according to any one of claims 1 to 9, wherein the preservative is sorbic acid or a salt thereof, preferably the salt of sorbic acid is potassium sorbate, and the at least one levulinic acid derivative and sorbic acid or a salt thereof are contained in the preservative composition in a weight ratio of from 500:1 to 1:
10.
12. 10. The preservative composition according to any one of claims 1 to 9, wherein the preservative is 3-iodo-2-propynyl butylcarbamate (IPBC), and the at least one levulinic acid derivative and 3-iodo-2-propynyl butylcarbamate (IPBC) are contained in the preservative composition in a weight ratio of 25:1 to 1:
2.
13. 10. The preservative composition according to any one of claims 1 to 9, wherein the preservative is alkyldimethylbenzylammonium chloride (ADBAC), and the at least one levulinic acid derivative and alkyldimethylbenzylammonium chloride (ADBAC) are present in the preservative composition in a weight ratio of 8000:1 to 500:
1.
14. 10. The preservative composition according to any one of claims 1 to 9, wherein the preservative is sodium pyrithione, and the at least one levulinic acid derivative and sodium pyrithione are contained in the preservative composition in a weight ratio of 8000:1 to 5:
1.
15. 10. The preservative composition according to any one of claims 1 to 9, wherein the preservative is lactic acid or a salt thereof, preferably the salt of lactic acid is sodium lactate, and the at least one levulinic acid derivative and lactic acid or a salt thereof are contained in the preservative composition in a weight ratio of from 60:1 to 1:
5.
16. The preservative composition according to any one of claims 1 to 9, wherein the preservative is dicarboxymethylalanine trisodium, and the at least one levulinic acid derivative and dicarboxymethylalanine trisodium are contained in the preservative composition in a weight ratio of 5:1 to 1:
5.
17. 10. The preservative composition according to any one of claims 1 to 9, wherein the preservative is dehydroacetic acid or a salt thereof, preferably the salt of dehydroacetic acid is sodium dehydroacetate, and the at least one levulinic acid derivative and dehydroacetic acid or a salt thereof are contained in the preservative composition in a weight ratio of 300:1 to 1:
10.
18. 10. The preservative composition according to any one of claims 1 to 9, wherein the preservative is a benzisothiazolinone, and the at least one levulinic acid derivative and the benzisothiazolinone are contained in the preservative composition in a weight ratio of from 200:1 to 1:
10.
19. 10. The preservative composition according to any one of claims 1 to 9, wherein the preservative is 2-hydroxypyridine-N-oxide, and the at least one levulinic acid derivative and 2-hydroxypyridine-N-oxide are contained in the preservative composition in a weight ratio of from 75:1 to 1:
1.
20. 10. The preservative composition according to any one of claims 1 to 9, wherein the preservative is poly(hexamethylene) biguanide, and the at least one levulinic acid derivative and the poly(hexamethylene) biguanide are present in the preservative composition in a weight ratio of 800:1 to 5:
1.
21. An end use formulation comprising a preservative composition according to any one of claims 1 to 20.
22. 22. The end use formulation of claim 21 having a pH of 4 or higher, preferably a pH of 6 or higher.
23. 23. The end-use formulation according to claim 21 or 22, wherein the preservative contained in the preservative composition is present in the end-use formulation in an amount of 1% by weight or less, such as 0.5% by weight or less, based on the weight of the end-use formulation.
24. 24. The end use formulation according to any one of claims 21 to 23, wherein the preservative is selected from acid compounds and their salts, aldehydes, phenolic compounds, sulfites, iron chelating agents, aromatic alcohols, quaternary ammonium compounds, pyrone compounds, urea compounds, guanidine compounds, pyridine compounds, imidazole compounds, isothiazolinone compounds, amine compounds, carbamate compounds, or any combination thereof.
25. 25. The end use formulation of any one of claims 21 to 24, wherein the preservative is selected from the group consisting of sodium benzoate, benzoic acid, potassium sorbate, sorbic acid, 3-iodo-2-propynyl butylcarbamate (IPBC), alkyldimethylbenzylammonium chloride (ADBAC), sodium pyrithione, lactic acid, sodium lactate, dicarboxymethylalanine trisodium, dehydroacetic acid, sodium dehydroacetate, benzisothiazolinone, 2-hydroxypyridine-N-oxide, poly(hexamethylene) biguanide, and combinations thereof.
26. The levulinic acid ester is 1~8 Alkyl levulinic acid ester, C 3~8 26. The end use formulation of any one of claims 21 to 25, which is a cycloalkyl levulinic acid ester, a cycloalkyl levulinic acid ester, or a combination thereof.
27. 27. The end use formulation of any one of claims 21 to 26, wherein the levulinate ester is ethyl levulinate, butyl levulinate, or a combination thereof.
28. 21. Use of a preservative composition according to any one of claims 1 to 20 for increasing effectiveness against microorganisms compared to an equivalent amount of the preservative not comprising said at least one levulinic acid derivative.
29. Use of at least one levulinic acid derivative selected from (a) a levulinic acid ester, or (b) a levulinic acid ketal, and combinations thereof, to increase the effectiveness of at least one preservative against microorganisms compared to an equivalent amount of the preservative without the at least one levulinic acid derivative.
30. 30. Use according to claim 28 or 29, wherein the effectiveness against microorganisms is increased at pH 4-9 or higher compared to an equivalent amount of the preservative at pH 4-9 not comprising the at least one levulinic acid derivative, preferably the effectiveness against microorganisms is increased at pH 6-8 or higher compared to an equivalent amount of the preservative at pH 6-8 not comprising the at least one levulinic acid derivative.
31. The use according to any one of claims 28 to 30, wherein the efficacy is increased by at least a 0.5 log decrease, more preferably by at least a 1.0 log decrease.
32. 32. The use according to any one of claims 28 to 31, wherein the preservative is selected from acid compounds and their salts, aldehydes, phenolic compounds, sulfites, iron chelating agents, aromatic alcohols, quaternary ammonium compounds, pyrone compounds, urea compounds, guanidine compounds, pyridine compounds, imidazole compounds, isothiazolinone compounds, amine compounds, carbamate compounds, or any combination thereof.
33. 33. The use of any one of claims 28 to 32, wherein the preservative is selected from the group consisting of sodium benzoate, benzoic acid, potassium sorbate, sorbic acid, 3-iodo-2-propynyl butylcarbamate (IPBC), alkyldimethylbenzylammonium chloride (ADBAC), sodium pyrithione, lactic acid, sodium lactate, dicarboxymethylalanine trisodium, dehydroacetic acid, sodium dehydroacetate, benzisothiazolinone, 2-hydroxypyridine-N-oxide, poly(hexamethylene) biguanide, and combinations thereof.
34. The levulinic acid ester is 1~8 Alkyl levulinic acid ester, C 3~8 The use according to any one of claims 28 to 33, wherein the levulinic acid ester is a cycloalkyl levulinic acid ester, ... or a combination thereof.
35. The use according to any one of claims 28 to 34, wherein the levulinic acid ester is ethyl levulinate, butyl levulinate, or a combination thereof.
36. A method for preventing microbial spoilage of an end-use formulation, comprising adding to said end-use formulation a preservative composition according to any one of claims 1 to 20.
37. 37. The method of claim 36, wherein the end use formulation has a pH of 4 or greater, preferably a pH of 6 or greater.
38. 38. The method of claim 36 or 37, wherein the preservative is selected from acid compounds and their salts, aldehydes, phenolic compounds, sulfites, iron chelating agents, aromatic alcohols, quaternary ammonium compounds, pyrone compounds, urea compounds, guanidine compounds, pyridine compounds, imidazole compounds, isothiazolinone compounds, amine compounds, carbamate compounds, or any combination thereof.
39. 39. The method of any one of claims 36 to 38, wherein the preservative is selected from the group consisting of sodium benzoate, benzoic acid, potassium sorbate, sorbic acid, 3-iodo-2-propynyl butylcarbamate (IPBC), alkyldimethylbenzylammonium chloride (ADBAC), sodium pyrithione, lactic acid, sodium lactate, dicarboxymethylalanine trisodium, dehydroacetic acid, sodium dehydroacetate, benzisothiazolinone, 2-hydroxypyridine-N-oxide, poly(hexamethylene) biguanide, and combinations thereof.
40. The levulinic acid ester is 1~8 Alkyl levulinic acid ester, C 3~8 40. The method of any one of claims 36 to 39, wherein the carboxylic acid ester is a cycloalkyl levulinic acid ester, ... or a combination thereof.
41. 41. The method of any one of claims 36 to 40, wherein the levulinate ester is ethyl levulinate, butyl levulinate, or a combination thereof.
Citation Information
Patent Citations
Anti-microbial ketocarboxylic acid esters - used in disinfectants and cosmetic creams, solns. or aerosols
DE2311675A1
4-hydroxy-3-alkoxybenzaldehyde 2, 3-butanediol acetal compounds and perfume composition containing the compound as active ingredient
JP2001002673A
Solvents, solutions, cleaning compositions and methods
JP2012528898A
Individualized health management formulations and manufacturing methods containing alkyl ketal esters
JP2013526532A
JPS4739056A
